In addition, the positive results seen in primary progressive MS, a very aggressive form of the disease, are very encouraging. We continue with aggressive development of our pipeline products. During the past quarter, we intensified our investment in the important new platform technology of genomics and expanded our long-term pipeline capabilities and basic research programs with several collaborative agreements. Reference is made in particular to statements regarding plans for future regulatory filings and commencement of clinical trials. These statements are based on the Company's current beliefs and expectations as to such future outcomes.
Drug development involves a high degree of risk.
Success in early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful. Factors which could cause actual results to differ materially from the Company's current expectations include the risk that a particular product may not show therapeutic effect or an acceptable safety profile in subsequent trials or may not meet applicable regulatory standards, or that problems or delays may arise in preparation for or during clinical trials or in the course of the development, testing or manufacturing of the product. Biogen, Inc., winner of the U.S. National Medal of Technology, is a biopharmaceutical company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. Biogen's research and development activities are focused on novel products to treat inflammatory and autoimmune diseases, neurological diseases, cancer, fibrosis and congestive heart failure. The Company maintains active clinical research programs in protein therapeutics, small molecules, genomics and gene therapy.